At variance from normal CB-derived CD34+ cells, where TIMP-1 was shown to affect only the clonogenic potential, in AML TIMP-1 exerts additional effects, such as improving cell survival and CXCL12-mediated migration. This evidence concerns the gene CD34 and acute myeloid leukemia.